Tricuspid Valve Repair Device Gains FDA Approval Despite Limited Trial Outcomes
The Pascal Precision transcatheter edge-to-edge repair system received FDA approval for treating severe tricuspid regurgitation based on a trial showing improved health status, though clinical endpoints were limited by early patient crossover to newer therapies. The device demonstrated a significant improvement in quality-of-life measures after six months, despite being hampered by changes in the study design due to competing treatments entering the market.
The Pascal Precision transcatheter edge-to-edge repair (TEER) system received FDA approval in November 2026 for treating severe tricuspid regurgitation (TR), based on results from the CLASP II TR trial conducted across the U.S. and Canada. The trial randomized 294 patients to receive Pascal Precision TEER plus optimal medical therapy and 148 to medical therapy alone, with a primary endpoint analyzed at six months due to early crossover in the control group—largely driven by the 2024 FDA approvals of competing devices like Evoque tricuspid valve replacement and TriClip G4 TEER. Despite this design shift, the trial demonstrated a significant win ratio of 1.98 favoring the device in a hierarchical composite endpoint, primarily due to a 10-point average improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at six months. At one year, 80% of TEER recipients achieved moderate or better TR reduction compared to only 30% in the medical therapy group. Safety data showed a 20.1% composite event rate at one year, with severe bleeding and cardiovascular mortality as notable concerns. The trial was open-label, raising potential placebo effects, and participating centers had limited prior experience with the device.
The approval follows earlier FDA clearance for Pascal Precision in mitral TEER (2022) and builds on a growing body of evidence from trials like TRILUMINATE, Tri.Fr, and TRIC-I-HF, which similarly show patient-reported benefits from tricuspid interventions. Key
The FDA’s approval of Pascal Precision for tricuspid regurgitation could expand access to transcatheter repair for elderly patients with symptomatic severe TR, particularly those deemed high-risk for surgery. Given that nearly 60% of trial participants had NYHA class III-IV symptoms and a history of heart failure hospitalization, this intervention may alleviate suffering in a vulnerable population. However, the approval’s impact may be tempered by uncertainty around long-term outcomes and cost-effectiveness, especially as competing devices enter the market. The reliance on patient-reported outcomes—while meaningful—may influence clinical adoption differently than hard endpoints like mortality or hospitalization rates. This situation mirrors earlier debates over transcatheter mitral valve repair, where initial enthusiasm was followed by calls for more rigorous long-term data and clearer patient selection criteria. As with those devices, widespread use may depend on evolving registry dat